国家: 以色列
语言: 英文
来源: Ministry of Health
IDARUBICIN HYDROCHLORIDE
PFIZER PFE PHARMACEUTICALS ISRAEL LTD
L01DB06
POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION
IDARUBICIN HYDROCHLORIDE 10 MG/VIAL
I.V
Required
PFIZER INC, USA
IDARUBICIN
IDARUBICIN
Antimitotic and cytotoxic agent. Acute non-limphocytic Leukemia (ANLL) in adults for remission induction in untreated patients or for remission induction in relapsed or refractory patients.Acute limphocytic leukemia (ALL) as second line treatment in adults and children.
2023-02-28
העדוה העדוה לע לע הרמחה הרמחה ( ( עדימ עדימ ןולעב )תוחיטב ןולעב )תוחיטב ל ל אפור אפור ןכדועמ( ןכדועמ( 05.2013 05.2013 ) ) ךיראת 14/12/2014 םש רישכת תילגנאב רפסמו םושירה ZAVEDOS 10MG 059-92-27176-00 םש לעב םושירה : רזייפ הקיטבצמרפ מ"עב ספוט הז דעוימ טורפל תורמחהה דבלב ! תורמחהה תושקובמה קרפ ןולעב טסקט יחכונ טסקט שדח POSOLOGY AND METHOD OF ADMINISTRATION Idarubicin, as the reconstituted solution, must be administered only by the intravenous (IV) route (See section 6.5). A slow administration over 5 to 10 minutes via the tubing of a freely running intravenous infusion of 0.9% sodium chloride or 5% dextrose, must be followed. A direct push injection is not recommended due to the risk of extravasation, which may occur even in the presence of adequate blood return upon needle aspiration (See section 4.4). • ANLL/AML. In adult ANLL/AML, the recommended intravenous dose schedule is 12 mg/ m2 daily for 3 days in combination with cytarabine. Idarubicin may also be administered as a single agent and in combination, at a dose of 8 mg/m2 daily for 5 days. • ALL. In adult ALL, the recommended single-agent intravenous dose is 12 mg/m2 daily for 3 days. In children with ALL, the recommended single-agent intravenous dose is 10 mg/m2 daily for 3 days. …. For intravenous use only. Not for intrathecal use. Dosage is calculated on the basis of body surface area. Acute non- lymphocyticlymphoblastic leukaemia (ANLL) Adults - 12 mg/m2/day i.v. daily for 3 days in combination with cytarabine. or - 8 mg/m2/day i.v. daily for 5 days with/without combination. Acute lymphocytic lymphoblastic leukaemia (ALL) Adults As single agent in ALL the suggested dose in adults is 12 mg/m2 i.v. daily for 3 days. Children 10 mg/m2 i.v. daily for 3 days, as a single agent. All of these dosage schedules should, however, take into account the haematologica 阅读完整的文件
Zavedos 10 mg LPD CC 22 May 2023 Page 1 of 10 - 2023-0084117 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Zavedos ® 10 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains10mg idarubicin hydrochloride. The reconstituted solution contains 1mg/ml. Excipients with known effect: Each vial contains 100mg of lactose anhydrous. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for concentrate for solution for infusion Sterile, pyrogen-free, orange-red, freeze-dried powder in vial containing 10mg of idarubicin hydrochloride, with 100mg of lactose anhydrous. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Antimitotic and cytotoxic agent. Acute non-lymphocytic leukemia (ANLL) in adults for remission induction in untreated patients or for remission induction in relapsed or refractory patients. Acute lymphocytic leukemia (ALL) as second- line treatment in adults and children. 4.2 Posology and method of administration For intravenous use only. Not for intrathecal use. Dosage is calculated on the basis of body surface area. Acute non- lymphocytic leukaemia (ANLL) _ _ _ _ _Adults_ - 12 mg/m 2 /day i.v. daily for 3 days in combination with cytarabine. or - 8 mg/m 2 /day i.v. daily for 5 days with/without combination. Acute lymphocytic leukaemia (ALL) _ _ _ _ _Adults_ As single agent in ALL _ _ the suggested dose in adults is 12 mg/m 2 i.v. daily for 3 days. _ _ _ _ _Children_ 10 mg/m 2 i.v. daily for 3 days, as a single agent. All of these dosage schedules should, however, take into account the haematological status of the patient and the dosages of other cytotoxic drugs when used in combination. Zavedos 10 mg LPD CC 22 May 2023 Page 2 of 10 - 2023-0084117 Administration of a second course should be delayed in patients who develop severe mucositis until recovery from this toxicity has occurred and a dose reduction of 25% is recommended. For directions on dilution of the product before administration, see section 6.6. 4.3 Contraindications • known hypersensi 阅读完整的文件